These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 749189)
1. [Possibilities and limitations of immunotherapy in the treatment of malignant neoplasms]. Chapuis B; Barrelet L; Dialdas J Schweiz Med Wochenschr; 1978 Dec; 108(49):1935-8. PubMed ID: 749189 [TBL] [Abstract][Full Text] [Related]
2. [Problems of the immunotherapy of malignant neoplasma]. Trapeznikov NN; Iavorskiĭ VV Klin Med (Mosk); 1975 May; 52(5):15-22. PubMed ID: 1094178 [No Abstract] [Full Text] [Related]
3. [Tumor rejection antigen and cancer immunotherapy]. Matsutake T; Nakayama E Gan To Kagaku Ryoho; 1995 Nov; 22(13):1871-7. PubMed ID: 7487115 [TBL] [Abstract][Full Text] [Related]
4. [Discovery of the splicing of peptides by the proteasome and study of preclinical models of anticancer immunotherapy]. Van den Eynde B Bull Mem Acad R Med Belg; 2007; 162(5-6):352-6. PubMed ID: 18405005 [TBL] [Abstract][Full Text] [Related]
5. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
6. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011 [TBL] [Abstract][Full Text] [Related]
7. The present status of immunodiagnosis and immunotherapy of cancer. Pasternak G Arch Geschwulstforsch; 1981; 51(4):284-93. PubMed ID: 7032448 [TBL] [Abstract][Full Text] [Related]
8. [Possibilities of immunotherapy of human tumors]. Fekete B Orv Hetil; 1992 Sep; 133(36):2271-3. PubMed ID: 1408060 [No Abstract] [Full Text] [Related]
9. [Current status of immunotherapy in oncology]. Zielinski C Acta Med Austriaca; 1991; 18(1):20-4. PubMed ID: 1713730 [TBL] [Abstract][Full Text] [Related]
10. The immune response and cancer. A guide. Gilbert HA; Kagan AR Radiol Clin Biol; 1974; 43(5):409-44. PubMed ID: 4605271 [No Abstract] [Full Text] [Related]
11. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy. Singh R; Paterson Y Expert Rev Vaccines; 2006 Aug; 5(4):541-52. PubMed ID: 16989634 [TBL] [Abstract][Full Text] [Related]
12. Development of optimized cryptic peptides for immunotherapy. Menez-Jamet J; Kosmatopoulos K IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883 [TBL] [Abstract][Full Text] [Related]
13. [Theoretical and experimental bases for the complex treatment of neoplasms]. Kavetskiĭ RE Vopr Onkol; 1973; 19(1):10-7. PubMed ID: 4121907 [No Abstract] [Full Text] [Related]
14. Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer. Gross S; Walden P Immunol Lett; 2008 Feb; 116(1):7-14. PubMed ID: 18164076 [TBL] [Abstract][Full Text] [Related]
16. Development of vaccines against self-antigens: the p53 paradigm. Chada S; Mhashilkar A; Roth JA; Gabrilovich D Curr Opin Drug Discov Devel; 2003 Mar; 6(2):169-73. PubMed ID: 12669451 [TBL] [Abstract][Full Text] [Related]
17. [Immunology: new approaches to immuno-modulation and immunotherapy]. Kabelitz D Dtsch Med Wochenschr; 2006 Jun; 131(25-26):1471-3. PubMed ID: 16794979 [No Abstract] [Full Text] [Related]
18. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Rosenberg SA Cancer J Sci Am; 1995; 1(2):90-100. PubMed ID: 9166458 [TBL] [Abstract][Full Text] [Related]
19. Radiation therapy and immunotherapy: the value of immunotherapy in the control of local and regional cancer. Cancer; 1976 Apr; 37(4 Suppl):2108-19. PubMed ID: 769945 [No Abstract] [Full Text] [Related]